| In 000€ | Materialise
Software |
Materialise
Medical |
Materialise
Manufacturing |
Total
segments |
Unallocated (1) | Consolidated | ||||||||||||
| For the three months ended December 31, 2022 | ||||||||||||||||||
| Revenues | 11,699 |
|
24,254 |
|
26,750 |
|
62,703 |
|
0 |
|
62,703 |
|
||||||
| Segment (adj) EBITDA | (1,441 |
) |
6,355 |
|
1,506 |
|
6,421 |
|
(2,163 |
) |
4,258 |
|
||||||
| Segment (adj) EBITDA % | -12.3 |
% |
26.2 |
% |
5.6 |
% |
10.2 |
% |
6.8 |
% |
||||||||
| For the three months ended December 31, 2021 | ||||||||||||||||||
| Revenues | 12,183 |
|
20,682 |
|
24,124 |
|
56,989 |
|
(0 |
) |
56,989 |
|
||||||
| Segment (adj) EBITDA | 5,518 |
|
6,358 |
|
990 |
|
12,866 |
|
(2,376 |
) |
10,490 |
|
||||||
| Segment (adj) EBITDA % | 45.3 |
% |
30.7 |
% |
4.1 |
% |
22.6 |
% |
18.4 |
% |
||||||||
| In 000€ | Materialise
Software |
Materialise
Medical |
Materialise
Manufacturing |
Total
segments |
Unallocated
(1) |
Consolidated | ||||||||||||
| For the twelve months ended December 31, 2022 | ||||||||||||||||||
| Revenues | 43,688 |
|
84,846 |
|
103,489 |
|
232,023 |
|
0 |
|
232,023 |
|
||||||
| Segment (adj) EBITDA | 1,514 |
|
18,822 |
|
8,229 |
|
28,565 |
|
(9,551 |
) |
19,014 |
|
||||||
| Segment (adj) EBITDA % | 3.5 |
% |
22.2 |
% |
8.0 |
% |
12.3 |
% |
8.2 |
% |
||||||||
| For the twelve months ended December 31, 2021 | ||||||||||||||||||
| Revenues | 42,902 |
|
73,368 |
|
89,180 |
|
205,450 |
|
0 |
|
205,450 |
|
||||||
| Segment (adj) EBITDA | 15,705 |
|
20,669 |
|
6,275 |
|
42,648 |
|
(10,158 |
) |
32,490 |
|
||||||
| Segment (adj) EBITDA % | 36.6 |
% |
28.2 |
% |
7.0 |
% |
20.8 |
% |
15.8 |
% |
||||||||
| (1) Unallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses, acquisition related expenses of business combinations, impairments and fair value of business combinations that are included in Adjusted EBITDA. |
